Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Theidel, Ulrike, Väätäinen, Saku, Martikainen, Janne, Soini, Erkki, Hardt, Thomas, Doehner, Wolfram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/
https://www.ncbi.nlm.nih.gov/pubmed/28772041
http://dx.doi.org/10.1002/ehf2.12179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/
https://www.ncbi.nlm.nih.gov/pubmed/28772041
http://dx.doi.org/10.1002/ehf2.12179

Ejemplares similares